Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 11, 2018Frontiers in ImmunologyOpen Access

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRebekka WeberUniversity of MannheimVFViktor FlemingQueen's University BelfastXHXiaoying HuFujian Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Weber et al. (2018) studied this question.

synapsesocial.com/papers/69d8efae183921ebcaae40behttps://doi.org/10.3389/fimmu.2018.01310
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Myeloid‐derived suppressor cell heterogeneity in human cancers2014 · 389 citations
  2. 2AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer2015 · 453 citations
  3. 3Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response2007 · 853 citations
  4. 4Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors2016 · 145 citations
  5. 5The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation2008 · 250 citations